We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

BioVendor Group

BioVendor Group is an international group of biotechnology companies (BioVendor LM, BioVendor R&D, TestLine, ViennaLa... read more Featured Products: More products

Download Mobile App





BioVendor Presents Its Portfolio of IVD Products and Technologies for Lab Automation

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: KleeYa fully automated CLIA solution (Photo courtesy of BioVendor Group)
Image: KleeYa fully automated CLIA solution (Photo courtesy of BioVendor Group)

BioVendor Group (Brno, Czech Republic) celebrated its 30th anniversary by presenting its key product portfolio, including CLIA, NGS, Microblot Array, microRNA and LAMP products, at ECCMID 2022.

In the NGS field, BioVendor showcased its new technology fastGEN for examination of the mutation status of oncomarkers in samples. The technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The company presented its user-friendly diagnostic kits with software solution for KRAS, NRAS, BRAF, EGFR and IDH 1/2 genes with excellent analytical parameters and fast processing. BioVendor demonstrated its GENOVESA software fastGEN module, a cloud all-in-one solution for the analysis of raw data (FASTQ files) with technical and application support.

Among its solutions for multiplex diagnostics, BioVendor presented Microblot-Array (MBA), a new generation of a market-unique immunoblot array in a microtiter plate format. MBA is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which is time and cost-saving. The technology eliminates the limited capacity of traditional BLOT strips and opens the way to high throughput testing. Simple processing can be done manually or automatically using any open ELISA analyzers. The comprehensive evaluation is ensured by the TestLine Reader and Software (SW) for complex image analysis, including results evaluation and connectivity to LIS. BioVendor also showcased its LAMP Assays for the direct detection of target nucleic acids without the need of the isolation step. The unique architecture of the LAMP method ensures its high sensitivity and specificity and a tolerance for inhibitory substances

BioVendor provided a virtual tour of its KleeYa automated CLIA analyzer that offers an attractive portfolio of innovative and established diagnostic parameters and provides a comprehensive chemiluminescence system for diagnostic laboratories. With a graphical user interface, users can learn to control the fully automated system in minutes. KleeYa software is designed to minimize the burden on laboratory staff. Thanks to augmented reality, technical support is available to users at any time, right in the lab with advise on operation, settings and minor service tasks.

Related Links:
BioVendor Group

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.